Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The Company's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics). Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil) and others. The Company is one of the largest pharmaceutical companies by both market cap and sales.

Company Growth (employees)
Basel, CH
Size (employees)
121,000 (est)+2%
Novartis was founded in 1996 and is headquartered in Basel, CH

Key People/Management at Novartis

Joseph Jimenez

Joseph Jimenez

Chief Executive Officer of Novartis
Steven Baert

Steven Baert

Head of Human Resources of Novartis
Harry Kirsch

Harry Kirsch

Chief Financial Officer of Novartis
Erwin Vanhaecke

Erwin Vanhaecke

Head Novartis Group Quality
Michael Willi

Michael Willi

Group Head of Communications
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research (NIBR
Paul Hudson

Paul Hudson

CEO, Novartis Pharmaceuticals
Bruno Strigini

Bruno Strigini

CEO, Novartis Oncology
F. Ball

F. Ball

CEO, Alcon
Felix Ehrat

Felix Ehrat

Group General Counsel of Novartis
Richard Francis

Richard Francis

CEO, Sandoz
Vasant Narasimhan

Vasant Narasimhan

Global Head Drug Development and Chief Medical Officer for Novartis
André Wyss

André Wyss

President, Novartis Operations Country President for Switzerland
Patrice Matchaba

Patrice Matchaba

Global Head of Corporate Responsibility for Novartis
Peter Elam

Peter Elam

Head of Internal Audit
Bruno Heynen

Bruno Heynen

Secretary to the Executive Committee Novartis
Shannon Klinger

Shannon Klinger

Chief Ethics and Compliance Officer of Novartis and Head of Litigation for Novartis
Stephen Moran

Stephen Moran

Global Head of Strategy for Novartis

Novartis Office Locations

Novartis has offices in Basel, East Hanover, New York, Wehr and in 2 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Beijing, CN
14th floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
Wehr, DE
Oeflingerstrasse 44
Tokyo, JP
Toranomon Hills, Mori Tower, 1-23-1, Toranomon, Minato-ku
East Hanover, US
1 Health Plazam, Bldg. 101
New York, US
230 Park Avenue, 21st Floor
Show all (6)

Novartis Financials and Metrics

Novartis Financials

Novartis's revenue was reported to be $48.5 b in FY, 2016 which is a 2% decrease from the previous period.

Revenue (FY, 2016)

48.5 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

31 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

6.7 b

Market capitalization (31-Jan-2017)

175.5 b

Closing share price (31-Jan-2017)

Novartis's current market capitalization is $175.5 b.
USDFY, 2014FY, 2015FY, 2016


53.6 b49.4 b48.5 b

Revenue growth, %


Cost of goods sold

17.3 b17.4 b17.5 b

Gross profit

36.3 b32 b31 b
USDFY, 2015FY, 2016

Cash From Operating Activities

12.1 b11.5 b
USDY, 2016


407.7 k
Show all financial metrics

Novartis Operating Metrics

Y, 2015Y, 2016

Patients Reached

972 m965 m

Projects Entering Development Pipeline


Major Submissions (US, EU, JP)


Major Approvals (US, EU, JP)

Show all operating metrics

Novartis Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Advanced Accelerator ApplicationsOctober 30, 2017$3.9 b

Novartis Market Value History

Novartis Revenue Breakdown

Novartis Median Salaries

Source: 453 public H-1B filings from Novartis

Novartis's Web-traffic and Trends

Novartis Online and Social Media Presence

Novartis News and Updates

Seeking to expand CAR-T's reach, Novartis snags new regulatory milestones for Kymriah

Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field.

Small Molecule API Market Demonstrate Immense Growth Potential at ~7.0% of CAGR By 2027

The report titled “Small Molecule API Market -Forecast to 2027″ is a direct appreciation by Market Research Future of the market potential of the Small Molecule API Market. The report intends to provide accurate and meaningful insights, both quantitative as well as qualitative. It can be said with h…

US Polycystic Ovary Syndrome Treatment Market is Expected to Expand US$ 313.2 Mn during 2016-2024

U.S Market Study on Polycystic Ovarian Syndrome Treatment: Insulin Sensitizing Agents Drug Class Segment Projected to Reflect Highest Market Attractiveness Index Through 2024 Posted via Industry Today. Follow us on Twitter @IndustryToday

Colorectal Cancer Market in Middle-East and Africa by Surgery, Radiation, Chemotherapy, Targeted Drug Therapy and Forecasts Till 2022

The Middle-East and Africa Colorectal Cancer Market report is a comprehensive analysis report provide detailed analysis of the market structure along with forecast for the next 5 years of the various segments and sub-segments of the Middle-East and Africa Colorectal Cancer Industry. Posted via Indus…

World Osteosarcoma Industry is Projected to Reach at a CAGR over ~8.7% by 2023

World Osteosarcoma Industry Information: By Type (Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extra-Skeletal Osteosarcoma), By Diagnosis (X-Ray, Ct Scan, Mri), By Treatment (Drugs, Surgery, Chemotherapy), and By End User- Global Forecast till 2023 Posted via Industry Today. Follow us on…

Payers point to Spark’s gene therapy as a model for innovative pricing plans

When Spark Therapeutics announced an $850,000 price for its gene therapy Luxturna last week, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the J.P. Morgan Healthcare conference this week, it was clear that sent…
Show more

Novartis Company Life and Culture

You may also be interested in